Current status of therapy for breast cancer worldwide and in Japan

Table 3 Adjuvant trials of trastuzumab

Trial	Regimen	DFS	OS
HERA[11]	CT alone	36% events reduction, HR = 0.64,	2HR = 0.66, P = 0.0115 at 2 yr
	CT + H 1 yr	P < 0.0001 at 2 yr
NSABP B-31 and	AC × 4 → P × 4	52% events reduction, HR = 0.48,	33% mortality reduction;
NCCTG N-9831[12]	AC × 4 → P × 4 + H1	P < 0.0001 at 2 yr	HR = 0.66, P = 0.015 at 2 yr
BCIRG 006[13]	AC × 4 → T × 4	HR = 0.61, P < 0.00013	HR = 0.59, P < 0.0043
	AC × 4 → T × 4 + H2	HR = 0.67, P = 0.00033	HR = 0.66, P = 0.00173
	T + Carbo × 6 + H2	At 3 yr	At 3 yr

AC: Doxorubicin + cyclophosphamide; BCIRG: Breast Cancer International Research Group; Carbo: Carboplatin; CT: Chemotherapy; DFS: Disease-free survival; FEC: Fluorouracil + epirubicin + cyclophosphamide; FinHer: Finland Herceptin; H: Trastuzumab; HERA: Herceptin Adjuvant; HR: Hazard ratio; NCCTG: North Central Cancer Treatment Group; NSABP: National Surgical Adjuvant Breast and Bowel Project; OS: Overall survival; P: Paclitaxcel; T: Docetaxel.

¹Total of 52 wk beginning with paclitaxel;

²Weekly during docetaxel treatment and then every 3 wk for 1 year;

³Compared with AC × 4 → T × 4.